Helix BioPharma Corp. saw a modest increase in stock price amid a challenging year.
This week, Helix BioPharma Corp. (HBP.TO) closed at C$1.40, reflecting a 2.14% gain for the day. However, the stock has declined by 0.69% over the past week and is down 40.42% year-to-date. Despite the recent uptick, the overall performance in 2023 suggests ongoing challenges for the company.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$151.99M
52W high
$5.40
52W low
$1.10
1W change
-3.00%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 28.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+28.9% Upside
Current Price
C$1.94
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
40.0%
Annualized
90-Day Vol
58.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.32
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.06 | C$1.79 โ C$2.36 |
| 60 trading days | C$2.19 | C$1.80 โ C$2.66 |
| 90 trading days | C$2.32 | C$1.83 โ C$2.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors in Helix BioPharma Corp. should consider the stock's recent performance and the broader market context, especially as the company navigates its financial landscape and strategic initiatives.
Helix BioPharma Corp. Sees 40.42% Decline YTD
With a market cap of C$106.93 million and a beta of -0.35, Helix BioPharma's stock has shown lower volatility compared to the broader market, reflecting its niche position in the healthcare sector.
Bull case
Analysts are optimistic about Helix BioPharma, with an average price target of C$2.50, indicating significant upside potential. The company's efforts to secure financing for its therapeutic programs may also support future growth.
Bear case
Despite the potential for growth, Helix BioPharma's negative profit margin and return on equity raise concerns about its financial health. Additionally, the stock's significant decline this year may deter risk-averse investors.
Recent Price Action
Helix BioPharma Corp. (HBP.TO) experienced a 2.14% increase today, closing at C$1.40. Over the past week, the stock has declined by 0.69%, and it remains significantly lower compared to its year-to-date performance, which shows a drop of 40.42%. Despite the recent gain, the stock continues to reflect the challenges faced by the company in a competitive healthcare sector.
Catalysts and Company News
Advertisement
There were no major company news announcements this week that might have influenced the stock price. However, Helix BioPharma has previously reported on its financial results and interim statements for the three- and nine-month periods ending April 30, 2026. Investors can find these details on the company's profile at SEDAR Plus and on their official website.
Technical Picture
From a technical standpoint, Helix BioPharma's stock is currently trading below its 50-day moving average of C$1.52, representing a 7.6% discount. The 200-day moving average stands at C$2.00, indicating a 30% decline from the current price. The stock's 52-week range is between C$0.95 and C$5.40, with the current price being approximately 10% of that range. The recent trading volume of 2,340 shares is slightly above the 20-day average of 1,208 shares, suggesting moderate interest among investors.
Insider Activity
There are no recent insider activity reports available for Helix BioPharma Corp.
Price Action Summary
As of the last close, Helix BioPharma Corp. (HBP.TO) stands at C$1.40, reflecting a 2.14% increase for the day. Investors should remain cautious, considering the stock's overall performance and market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
